US Patent 8158579 Fusion protein of an exendin to modified transferrin
Patent 8158579 was granted and assigned to BIOREXIS PHARMACEUTICAL CORPORATION on April, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+377 characters)
Article
Patent abstract
The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.
Edits on 21 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Andrew J. Turner0
Christopher P. Prior0
David James Ballance0
Homayoun Sadeghi0
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08158579 Fusion protein of an exendin to modified transferrin US Patent 8158579 Fusion protein of an exendin to modified transferrin
Infobox
Patent Number
08158579
Patent Number
8158579
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08158579 Fusion protein of an exendin to modified transferrin
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08158579
Date of patent
April 17, 2012
Patent application number
12956623
Date Filed
November 30, 2010
Patent primary examiner
Find more entities like US Patent 8158579 Fusion protein of an exendin to modified transferrin
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.